Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.68 |
| ▸ | CTSK | P43235 | 7/20 | 0.68 |
| ▸ | CTSB | P07858 | 2/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7311950 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL27502336 | 1.00 | CTSS (0.68) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL12826336 | 0.95 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL18235374 | 0.93 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL4420859 | 0.90 | REN (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7618822 | 0.90 | REN (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL2173588 | 0.90 | REN (0.67) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL66220 | 0.90 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL21473784 | 0.90 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL67020 | 0.90 | ACE (0.79) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942514-B | Method for preparing azalazavir sulfate intermediate | 淮海工学院 | 2022-09-09 | — | — | CN | claimed |
| CN-109942514-B | Method for preparing azalazavir sulfate intermediate | 淮海工学院 | 2022-09-09 | — | — | CN | disclosed |
| WO-2018065611-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | Oxford Drug Design Limited (GB) | 2018-04-12 | — | — | WO | disclosed |
| EP-1697308-B1 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7550481-B2 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1697308-A4 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | MERCK & CO INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070142634-A1 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1697308-A2 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005065195-A2 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| CN-1202096-C | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2005-05-18 | — | — | CN | disclosed |
| CN-1444572-A | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | AVENTIS PHARMA SA (FR) | 2003-09-24 | — | — | CN | disclosed |
| US-5387671-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1995-02-07 | — | — | US | disclosed |
| EP-0564533-A4 | MODIFIED HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LAB (US) | 1994-11-02 | — | — | EP | disclosed |
| EP-0564533-A1 | MODIFIED PENTA- AND HEXAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1993-10-13 | — | — | EP | disclosed |
| WO-1992012168-A1 | MODIFIED HEXA- AND HEPTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1992-07-23 | — | — | WO | disclosed |
| US-5095114-A | Process for the enantiomer-selective preparation of γ-keto-δ-amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0408881-A2 | Process for the enantioselective preparation of gamma-keto-delta-amino-acid derivatives | MERCK PATENT GmbH (DE) | 1991-01-23 | — | — | EP | disclosed |
| US-4826815-A | HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| US-4645759-A | HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1987-02-24 | — | — | US | disclosed |
| EP-0172347-A2 | Renin inhibiting compounds | ABBOTT LABORATORIES (US) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142634-A1 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, APP | CTSS 143/4885CTSK 317/4885CTSB 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.